Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ FRS3 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5101324
Description
Antibody detects endogenous levels of total SNT2.
FRS3 (fibroblast growth factor receptor substrate 3), also known as FRS2B (FRS2-beta), is a 492 amino acid lipid-anchor adapter protein that contains one IRS-type PTB domain. Colocalizing to neural tissues with Tuj1, FRS3 functions as a feedback inhibitor of EGFR family members by preventing heterodimer formation between EGFR and ErbB2, thereby acting as a potential tumor suppressor. FRS3 is phosphorylated upon stimulation by FGF-2 or NGF and, acting as an adapter protein, links c-Fgr and NGF receptors to downstream signaling pathways. Interfering with the phosphorylation and nuclear translocation of ERK-2, FRS3 down-regulates ERK-2 expression. FRS3 likely interacts directly with GRB2, SH-PTP2, Flg, and Trk A, and may be involved in MAP kinase activation.
Specifications
FRS3 | |
Polyclonal | |
Unconjugated | |
FRS3 | |
4930417B13Rik; AI449674; FGFR substrate 3; FGFR-signaling adaptor SNT2; Fibroblast growth factor receptor substrate 3; FRS2B; Frs2beta; FRS2-beta; FRS3; Snt2; SNT-2; Suc1-associated neurotrophic factor target 2; suc1-associated neurotrophic factor target 2 (FGFR signalling adaptor); testicular tissue protein Li 71 | |
Rabbit | |
Affinity chromatography | |
RUO | |
10817 | |
-20°C | |
Liquid |
Western Blot, Immunocytochemistry | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
O43559 | |
FRS3 | |
A synthesized peptide derived from human FRS3(Accession O43559), corresponding to amino acid residues E199-A249. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction